{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:46:09Z","timestamp":1788547569196,"version":"build-2803163510"},"reference-count":32,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":3349,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregabalin is a novel compound that has been shown to have efficacy in the treatment of generalised anxiety disorder and is licensed for the treatment of the disorder in the European Union.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      The current study was designed to evaluate the safety and efficacy of pregabalin, an \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      \u03b4-ligand, in the treatment of generalised anxiety disorder in people 65 years and older.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This was a double-blind, randomised (2:1), placebo-controlled, 8-week trial of pregabalin, in flexible doses of 150\u2013600 mg\/day, in the treatment of DSM\u2013IV generalised anxiety disorder with a baseline Hamilton Rating Scale for Anxiety (HRSA) total score \u2a7e20. The primary outcome was end-point (week 8 or last visit, with last observation carried forward (LOCF)) change in HRSA total score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 273 patients (women, 78%; mean age, 72 years (s.d.=6); mean baseline HRSA total score, 26 (s.d.=4.6)) were randomised and received study treatment. On the primary intent-to-treat LOCF analysis, pregabalin was associated with a 2-point greater reduction in HRSA total score than placebo (12.87\n                      <jats:italic>v.<\/jats:italic>\n                      10.7;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.05). In a\n                      <jats:italic>post hoc<\/jats:italic>\n                      repeated measures mixed-effect model analysis, pregabalin was associated with significantly greater improvement than placebo in the HRSA total score from week 2 (\u20139.8 (s.d.=0.6)\n                      <jats:italic>v.<\/jats:italic>\n                      \u22127.2 (s.d.=0.8);\n                      <jats:italic>P<\/jats:italic>\n                      =0.0052) through week 8 (\u201314.4 (s.d.=0.6)\n                      <jats:italic>v.<\/jats:italic>\n                      \u221211.6 (s.d.=0.8);\n                      <jats:italic>P<\/jats:italic>\n                      =0.0070). Significant improvement was observed in the pregabalin group on both the HRSA psychic and somatic anxiety factors. There was a significantly greater decrease from baseline in mean Hamilton Rating Scale for Depression (HRSD) score with pregabalin compared with placebo (\u20135.48 (s.d.=0.46)\n                      <jats:italic>v.<\/jats:italic>\n                      \u22124.02 (s.d.=0.59);\n                      <jats:italic>P<\/jats:italic>\n                      =0.041). Pregabalin was well-tolerated, with almost all adverse events in the mild-to-moderate range, and self-limiting (median duration of 4\u201316 days). Discontinuations due to adverse events were similar for pregabalin (10.7%) and placebo (9.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pregabalin, in doses of 150\u2013600 mg\/day, was a safe and effective treatment of generalised anxiety disorder in patients 65 years and older. The anxiolytic efficacy of pregabalin had an early onset (by 2 weeks) and significantly improved both psychic and somatic symptoms of anxiety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.bp.107.037788","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T19:23:01Z","timestamp":1225480981000},"page":"389-394","source":"Crossref","is-referenced-by-count":110,"title":["Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder"],"prefix":"10.1192","volume":"193","author":[{"given":"Stuart","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krai","family":"Chatamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Pauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Baldinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000015038_ref5","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.1.115"},{"key":"S0007125000015038_ref2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(1998100)13:10<717::AID-GPS857>3.0.CO;2-M"},{"key":"S0007125000015038_ref8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.157.1.89"},{"key":"S0007125000015038_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.04.010"},{"key":"S0007125000015038_ref15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0511"},{"key":"S0007125000015038_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(97)83297-X"},{"key":"S0007125000015038_ref14","article-title":"Safety of benzodiazepines in the geriatric population","volume":"3","author":"Madhusoodanan","year":"2004","journal-title":"Expert Opin Drug Safe"},{"key":"S0007125000015038_ref30","volume-title":"Categorical Data Analysis Using the SAS System","author":"Stokes","year":"1995"},{"key":"S0007125000015038_ref28","volume-title":"Applied Linear Statistical Models.","author":"Neter","year":"1990"},{"key":"S0007125000015038_ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1179"},{"key":"S0007125000015038_ref4","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008351"},{"key":"S0007125000015038_ref12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.146"},{"key":"S0007125000015038_ref29","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"1989"},{"key":"S0007125000015038_ref32","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.3.269"},{"key":"S0007125000015038_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00531.x"},{"key":"S0007125000015038_ref24","article-title":"Effectiveness of the Hamilton Anxiety Rating Scale with older Generalized Anxiety Disorder patients","volume":"5","author":"Bech","year":"1999","journal-title":"J Clin Geropsychol"},{"key":"S0007125000015038_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000155820.74832.b0"},{"key":"S0007125000015038_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1001"},{"key":"S0007125000015038_ref3","first-page":"17","volume-title":"Anxiety in the Elderly: Treatment and Research","author":"Blazer","year":"1991"},{"key":"S0007125000015038_ref19","volume-title":"Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance","year":"1996"},{"key":"S0007125000015038_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702006104"},{"key":"S0007125000015038_ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522020-00002"},{"key":"S0007125000015038_ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50003.x"},{"key":"S0007125000015038_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.1022"},{"key":"S0007125000015038_ref20","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM\u2013IV).","year":"1994"},{"key":"S0007125000015038_ref21","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S0007125000015038_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0007125000015038_ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000015038_ref26","volume-title":"ECDEU Assessment Manual for Psychopharmacology.","author":"Guy","year":"1976"},{"key":"S0007125000015038_ref27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.160.2.206"},{"key":"S0007125000015038_ref31","doi-asserted-by":"publisher","DOI":"10.1080\/10401230590932335"},{"key":"S0007125000015038_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084032.22282.ff"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000015038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T18:04:13Z","timestamp":1556647453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000015038\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0007125000015038"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.107.037788","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1138021.618819","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1138021.595136","asserted-by":"object"}]},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}